Julie Vadboncoeur
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Julie Vadboncoeur has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
Annie-Claude Labbé
Division of Infectious Diseases and Medical Microbiology, Hôpital Maisonneuve-Rosemont (HMR), CIUSSS de l'Est-de-l'Île-de-Montréal, Montreal, Que.; Department of Microbiology, Infectious Diseases and Immunology, Faculty of Medicine, Montreal, Que
2 shared publicationsKahina Chibane
2 shared publications- Marie-Josée Aubin
Department of Ophthalmology, Université de Montréal, Montreal, QC H3T 1J4, Canada
2 shared publications - Mélanie Hébert
Department of Ophthalmology, Hôpital du Saint-Sacrement, Chu de Québec – Université Laval, Quebec City, Canada
2 shared publications Albert T. Vitale
John A. Moran Eye Center, University of Utah , Salt Lake City , UT , USA
1 shared publication- Bouchra Serhir
Laboratoire de santé publique du Québec/Institut national de santé publique du Québec, Sainte-Anne-de-Bellevue, QC, Canada
1 shared publication
Latest Publications
- 25 May 2026
- Published by Elsevier in Canadian Journal of Ophthalmology
- Vol. 61 (5) , 1307-1308
Widefield fundus imaging and OCT of bilateral laser-induced retinopathy
- 25 May 2026
- Published by Elsevier in Canadian Journal of Ophthalmology
- Vol. 61 (5) , 1307-1308
Widefield fundus imaging and OCT of bilateral laser-induced retinopathy
- 26 February 2026
- Published by Elsevier in Canadian Journal of Ophthalmology
- Vol. 61 (3) , 795-796
Primary ocular lymphoma misdiagnosed as diffuse anterior scleritis
- 26 February 2026
- Published by Elsevier in Canadian Journal of Ophthalmology
- Vol. 61 (3) , 795-796
Primary ocular lymphoma misdiagnosed as diffuse anterior scleritis
- 23 October 2022
- Published by Elsevier in Canadian Journal of Ophthalmology
- Vol. 58 (3) , e122-e124
Multiple evanescent white dot syndrome following COVID-19 vaccines
- 23 October 2022
- Published by Elsevier in Canadian Journal of Ophthalmology
- Vol. 58 (3) , e122-e124
Multiple evanescent white dot syndrome following COVID-19 vaccines
- Open Access
Recurrent and De Novo Toxoplasmosis Retinochoroiditis following Coronavirus Disease 2019 Infection or Vaccination
This study reports three cases of toxoplasmosis retinochoroiditis following coronavirus disease 2019 (COVID-19) infection or vaccination from the national Canadian COVID-19 Eye Registry between December 2020 and September 2021. A 56-year-old male presented 15 days after a positive COVID-19 test with toxoplasmosis retinochoroiditis. He later relapsed 8 days following a first Pfizer-BioNTech vaccine dose. Two patients presented with toxoplasmosis retinochoroiditis following COVID-19 vaccination: A 58-year-old female presenting 4 days following a first Pfizer-BioNTech vaccine dose with anterior uveitis and a posterior pole lesion discovered 3 months later and a 39-year-old female presenting 17 days after a first Moderna vaccine dose. Resolution was achieved with oral clindamycin, oral trimethoprim/sulfamethoxazole, and topical prednisolone acetate 1%. Patients were offered prophylactic trimethoprim/sulfamethoxazole for subsequent doses without relapse. Following COVID-19 infection or vaccination, patients may be at risk for toxoplasmosis retinochoroiditis. Prophylactic antibiotics for future doses may be offered to patients with known ocular toxoplasmosis to prevent recurrence.
Open AccessRecurrent and De Novo Toxoplasmosis Retinochoroiditis following Coronavirus Disease 2019 Infection or Vaccination
This study reports three cases of toxoplasmosis retinochoroiditis following coronavirus disease 2019 (COVID-19) infection or vaccination from the national Canadian COVID-19 Eye Registry between December 2020 and September 2021. A 56-year-old male presented 15 days after a positive COVID-19 test with toxoplasmosis retinochoroiditis. He later relapsed 8 days following a first Pfizer-BioNTech vaccine dose. Two patients presented with toxoplasmosis retinochoroiditis following COVID-19 vaccination: A 58-year-old female presenting 4 days following a first Pfizer-BioNTech vaccine dose with anterior uveitis and a posterior pole lesion discovered 3 months later and a 39-year-old female presenting 17 days after a first Moderna vaccine dose. Resolution was achieved with oral clindamycin, oral trimethoprim/sulfamethoxazole, and topical prednisolone acetate 1%. Patients were offered prophylactic trimethoprim/sulfamethoxazole for subsequent doses without relapse. Following COVID-19 infection or vaccination, patients may be at risk for toxoplasmosis retinochoroiditis. Prophylactic antibiotics for future doses may be offered to patients with known ocular toxoplasmosis to prevent recurrence.
- 1 April 2022
- Published by Elsevier in Canadian Journal of Ophthalmology
- Vol. 57 (2) , e40-E40
Retinal vasculitis after intravitreal injection of brolucizumab
- 1 April 2022
- Published by Elsevier in Canadian Journal of Ophthalmology
- Vol. 57 (2) , e40-E40
Retinal vasculitis after intravitreal injection of brolucizumab
- 5 June 2020
- Published by Wolters Kluwer Health in RETINAL Cases & Brief Reports
- Vol. 16 (4) , 466-469
ACUTE ZONAL OCCULT OUTER RETINOPATHY: A CASE REPORT OF REGRESSION AFTER AN INTRAVITREAL DEXAMETHASONE (OZURDEX) IMPLANT
Purpose: To report the use of the dexamethasone (Ozurdex, Allergan Inc) intravitreal implant in the management of acute zonal occult outer retinopathy. Methods: Observational case report. Results: A 63-year-old woman presented with a 10-year history of progressing bilateral, although asymmetric, visual impairment and scotomata with clinical and imaging findings compatible with acute zonal occult outer retinopathy. The right eye had recently progressed rapidly until macular involvement occurred with loss of visual acuity. Under our observation, progression toward the fovea in the left eye occurred, Ozurdex intravitreal implant treatment was offered and administered. Autofluorescence imaging documented resolution of the hyperautofluorescent borders and slight regression of the involved retina. An injection was repeated every 6 months for 3 injections, and after a follow-up period, 20 months after the first and 8 months after the last injection, no further signs of progression were observed in her left eye. Conclusion: The dexamethasone implant effectively achieved regression of active disease in a patient with longstanding, progressive acute zonal occult outer retinopathy.
- 5 June 2020
- Published by Wolters Kluwer Health in RETINAL Cases & Brief Reports
- Vol. 16 (4) , 466-469
ACUTE ZONAL OCCULT OUTER RETINOPATHY: A CASE REPORT OF REGRESSION AFTER AN INTRAVITREAL DEXAMETHASONE (OZURDEX) IMPLANT
Purpose: To report the use of the dexamethasone (Ozurdex, Allergan Inc) intravitreal implant in the management of acute zonal occult outer retinopathy. Methods: Observational case report. Results: A 63-year-old woman presented with a 10-year history of progressing bilateral, although asymmetric, visual impairment and scotomata with clinical and imaging findings compatible with acute zonal occult outer retinopathy. The right eye had recently progressed rapidly until macular involvement occurred with loss of visual acuity. Under our observation, progression toward the fovea in the left eye occurred, Ozurdex intravitreal implant treatment was offered and administered. Autofluorescence imaging documented resolution of the hyperautofluorescent borders and slight regression of the involved retina. An injection was repeated every 6 months for 3 injections, and after a follow-up period, 20 months after the first and 8 months after the last injection, no further signs of progression were observed in her left eye. Conclusion: The dexamethasone implant effectively achieved regression of active disease in a patient with longstanding, progressive acute zonal occult outer retinopathy.
- 1 February 2020
- Published by Elsevier in Canadian Journal of Ophthalmology
- Vol. 55 (1) , 30-37
Ocular syphilis: case series (2000–2015) from 2 tertiary care centres in Montreal, Canada
- 1 February 2020
- Published by Elsevier in Canadian Journal of Ophthalmology
- Vol. 55 (1) , 30-37
Ocular syphilis: case series (2000–2015) from 2 tertiary care centres in Montreal, Canada
- 2 October 2019
- Published by Taylor & Francis in Ocular Immunology and Inflammation
- Vol. 29 (1) , 149-153
The Utility of Lyme Testing in the Workup of Ocular Inflammation
(2019). The Utility of Lyme Testing in the Workup of Ocular Inflammation. Ocular Immunology and Inflammation. Ahead of Print.
- 2 October 2019
- Published by Taylor & Francis in Ocular Immunology and Inflammation
- Vol. 29 (1) , 149-153
The Utility of Lyme Testing in the Workup of Ocular Inflammation
(2019). The Utility of Lyme Testing in the Workup of Ocular Inflammation. Ocular Immunology and Inflammation. Ahead of Print.